HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Latent Autoimmune Diabetes in Adults: a case report.

Abstract
Latent Autoimmune Diabetes in Adults (LADA) is an autoimmune endocrine disorder in which despite the presence of antipancreatic islets antibodies in the moment of diagnostics, the progression to beta-cell secretory insufficiency is slow. It is often confused with others types of diabetes and therefore the management is frequently inadequate. We report a clinical case of a 23-year-old man with diagnosis of type 2 diabetes since 6 months ago, poorly controlled with a sulfonylurea, who initially presented 2 months ago from polyuria, polydipsia, and asthenia and 6 kg weight loss. History of past illness was negative, however, his mother relates exclusive breastfeeding during the first 15 days of life and later (until the 6 months) he was fed with infant formula (S-26). Family history revealed a first-degree relative (father) with diabetes mellitus secondary to steroid administration due to diagnosis of bone marrow hypoplasia. Also presents second-degree family history (uncle and grandfather) of type 2 diabetes mellitus. There were no pathologic findings at the physical examination. Anthropometry and laboratory tests were as follows: body mass index (BMI) = 19.66 kg/m, basal and postprandial glycemia = 108, and 276 mg/dL respectively, glycated haemoglobin = 8.9%, basal and postprandial C-peptide (2 hours) = 1.9, and 3.2 ng/mL, homeostasis model assessment of beta cell function: 87.5%, homeostasis model assessment of insulin resistance: 1.6. LADA presumptive diagnosis was confirmed with presence of autoantibodies anti-tyrosin-phosphatase and GAD65. At the time of diagnosis, individuals with LADA present an onset age <50, BMI <25 kg/m2, low magnitude postprandial and basal hyperglycemia, normal or close to normal C-peptide values, and thus not occur with acute hyperglycemic crises. Insulin therapy preserves pancreatic b-cell function, at the point that eventually prescribed insulin doses need to be reduced.
AuthorsValmore Bermúdez, Daniel Aparicio, Carlos Colmenares, Lianny Peñaranda, Yettana Luti, Daniela Gotera, Joselyn Rojas, Mayela Cabrera, Nadia Reyna, Manuel Velasco, Zafar H Israili
JournalAmerican journal of therapeutics (Am J Ther) 2010 May-Jun Vol. 17 Issue 3 Pg. 284-7 ISSN: 1536-3686 [Electronic] United States
PMID20224323 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Autoantibodies
  • Hypoglycemic Agents
  • Insulin
Topics
  • Age of Onset
  • Autoantibodies (blood)
  • Autoimmune Diseases (diagnosis, immunology)
  • Diabetes Mellitus (diagnosis, immunology)
  • Diabetes Mellitus, Type 2 (diagnosis)
  • Humans
  • Hypoglycemic Agents (administration & dosage, therapeutic use)
  • Insulin (administration & dosage, therapeutic use)
  • Insulin Resistance
  • Insulin-Secreting Cells (metabolism)
  • Male
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: